Business Context and Reporting Period
Company: Pyxis Oncology, Inc. (PYXS)
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2026
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Securities Issued: 19,600,153 shares of Common Stock and Common Warrants to purchase an equal number of shares.
- Purchase Price: $2.551 per share of Common Stock.
- Warrant Exercise Price: $3.289 per share.
- Gross Proceeds (Upfront): Approximately $50.0 million (before fees and expenses).
- Potential Additional Proceeds: Approximately $64.0 million if all Common Warrants are exercised in full for cash.
- Placement Agent: Wells Fargo Securities, LLC.
- Expected Closing Date: July 2, 2026.
Material Changes and Strategic Impact
The filing reports a significant capital raise intended to extend the Company's cash runway into the second quarter of 2027. The proceeds are designated to support the advancement of the lead clinical program, micvotabart pelidotin (MICVO), specifically through key clinical milestones in the Phase 1 monotherapy study for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Warrant Terms: The Common Warrants are exercisable on or after the earlier of (i) the date of first public disclosure of clinical data from the MICVO Phase 1 study, or (ii) October 1, 2026. They expire on July 2, 2029.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management anticipates the upfront proceeds will extend the cash runway to Q2 2027.
- Registration Rights: The Company entered into a Registration Rights Agreement requiring the filing of a registration statement for the resale of securities by October 2, 2026. Failure to meet registration deadlines may trigger liquidated damages.
- Risks: The transaction is subject to customary closing conditions. The securities are unregistered and sold under Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Monitor the timeline for the filing and effectiveness of the registration statement (deadline: October 2, 2026).
- Track the disclosure of clinical data from the MICVO Phase 1 study, as this triggers the exercisability of the warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for specific covenants and liquidated damages provisions.